Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Retained Earnings (2022 - 2025)

Axsome Therapeutics' Retained Earnings history spans 4 years, with the latest figure at -$1.3 billion for Q4 2025.

  • For Q4 2025, Retained Earnings fell 16.32% year-over-year to -$1.3 billion; the TTM value through Dec 2025 reached -$1.3 billion, down 16.32%, while the annual FY2025 figure was -$1.3 billion, 16.32% down from the prior year.
  • Retained Earnings for Q4 2025 was -$1.3 billion at Axsome Therapeutics, down from -$1.3 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at -$448.8 million in Q1 2022 and bottomed at -$1.3 billion in Q4 2025.
  • The 4-year median for Retained Earnings is -$869.7 million (2023), against an average of -$873.7 million.
  • The largest annual shift saw Retained Earnings plummeted 48.77% in 2024 before it fell 16.32% in 2025.
  • A 4-year view of Retained Earnings shows it stood at -$596.3 million in 2022, then plummeted by 40.12% to -$835.6 million in 2023, then plummeted by 34.37% to -$1.1 billion in 2024, then dropped by 16.32% to -$1.3 billion in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Retained Earnings are -$1.3 billion (Q4 2025), -$1.3 billion (Q3 2025), and -$1.2 billion (Q2 2025).